Related Experiment Video
Updated: Aug 14, 2026
06:08
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
Published on: March 21, 2025
Can percent free prostate-specific antigen reduce the need for prostate biopsy?
1Kaiser Permanente Northwest Region, Clackamas, OR, USA. LIEBERMANST@kpnwoa.mts.kpnw.org
Effective Clinical Practice : ECP
|May 2, 2000
Summary
Percent free prostate-specific antigen (PSA) improves prostate cancer screening specificity. This study confirms its effectiveness in managed care settings, similar to academic centers, aiding in reducing unnecessary biopsies.
Area of Science:
- Urology
- Oncology
- Medical Diagnostics
Background:
- Percent free prostate-specific antigen (PSA) has shown promise in enhancing prostate cancer screening specificity.
- Previous studies demonstrated its utility in academic settings.
Purpose of the Study:
- To evaluate the efficacy of percent free PSA in reducing biopsy rates within a managed care setting.
- To compare its performance against findings from academic medical centers.
Main Methods:
- A prospective blinded study was conducted at Kaiser Permanente facilities.
- Hybritech Tandem PSA and free PSA assays were utilized.
- 250 men aged over 40 with PSA levels between 4.0-10.0 ng/mL and confirmed diagnoses were analyzed.
Main Results:
- Median percent free PSA differed significantly between men with and without prostate cancer (13% vs. 17%, P = 0.001).
- A cutoff of 25% free PSA yielded 97% sensitivity and 13% specificity.
- These results were comparable to those from a prior multicenter study.
Conclusions:
- Percent free PSA is effective in enhancing prostate cancer testing specificity within a managed care environment.
- The findings align with those from academic medical centers, supporting its broader application.
- This marker can help optimize prostate cancer screening protocols.
